Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta‐analysis of randomized controlled trials
Aim To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM). Materials and Methods The PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) comparing teplizumab to placebo for T1DM that repor...
Saved in:
| Published in | Diabetes, obesity & metabolism Vol. 26; no. 7; pp. 2652 - 2661 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.07.2024
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Aim
To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM).
Materials and Methods
The PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) comparing teplizumab to placebo for T1DM that reported any of the following outcomes: (1) C‐peptide area under the curve (AUC); (2) glycated haemoglobin (HbA1c) levels; (3) insulin requirements; and (4) adverse events. Heterogeneity was examined with I2 statistics. p values <0.05 were taken to indicate statistical significance. The continuous endpoints were compared through the pooled mean difference (MD) and binary endpoints were assessed using risk ratios, both with 95% confidence intervals (CIs). Statistical analyses were performed using Review Manager Web software.
Results
Eight RCTs with 1052 patients (754 receiving teplizumab) were included. Teplizumab significantly increased the AUC of C‐peptide levels at 6 (MD 0.10 nmol/L, 95% CI 0.05, 0.16), 12 (MD 0.13 nmol/L, 95% CI 0.06, 0.20), 18 (MD 0.18 nmol/L, 95% CI 0.09, 0.27) and 24 months (MD 0.16 nmol/L, 95% CI 0.02, 0.31), significantly reduced HbA1c levels at 6 (MD −0.57%, 95% CI −1.07, −0.08) and 12 months (MD −0.31%, 95% CI −0.59, −0.02), and significantly reduced insulin requirements at 6 (MD −0.12 U/kg, 95% CI −0.16, −0.08), 12 (MD −0.11 U/kg, 95% CI −0.15, −0.07), 18 (MD −0.17 U/kg, 95% CI −0.26, −0.09) and 24 months (MD −0.11 U/kg, 95% CI −0.22, −0.01).
Conclusion
Teplizumab increases AUC of C‐peptide levels and decreases HbA1c levels and insulin use, without raising serious adverse event risk. |
|---|---|
| AbstractList | Aim
To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM).
Materials and Methods
The PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) comparing teplizumab to placebo for T1DM that reported any of the following outcomes: (1) C‐peptide area under the curve (AUC); (2) glycated haemoglobin (HbA1c) levels; (3) insulin requirements; and (4) adverse events. Heterogeneity was examined with I2 statistics. p values <0.05 were taken to indicate statistical significance. The continuous endpoints were compared through the pooled mean difference (MD) and binary endpoints were assessed using risk ratios, both with 95% confidence intervals (CIs). Statistical analyses were performed using Review Manager Web software.
Results
Eight RCTs with 1052 patients (754 receiving teplizumab) were included. Teplizumab significantly increased the AUC of C‐peptide levels at 6 (MD 0.10 nmol/L, 95% CI 0.05, 0.16), 12 (MD 0.13 nmol/L, 95% CI 0.06, 0.20), 18 (MD 0.18 nmol/L, 95% CI 0.09, 0.27) and 24 months (MD 0.16 nmol/L, 95% CI 0.02, 0.31), significantly reduced HbA1c levels at 6 (MD −0.57%, 95% CI −1.07, −0.08) and 12 months (MD −0.31%, 95% CI −0.59, −0.02), and significantly reduced insulin requirements at 6 (MD −0.12 U/kg, 95% CI −0.16, −0.08), 12 (MD −0.11 U/kg, 95% CI −0.15, −0.07), 18 (MD −0.17 U/kg, 95% CI −0.26, −0.09) and 24 months (MD −0.11 U/kg, 95% CI −0.22, −0.01).
Conclusion
Teplizumab increases AUC of C‐peptide levels and decreases HbA1c levels and insulin use, without raising serious adverse event risk. To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM). The PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) comparing teplizumab to placebo for T1DM that reported any of the following outcomes: (1) C-peptide area under the curve (AUC); (2) glycated haemoglobin (HbA1c) levels; (3) insulin requirements; and (4) adverse events. Heterogeneity was examined with I statistics. p values <0.05 were taken to indicate statistical significance. The continuous endpoints were compared through the pooled mean difference (MD) and binary endpoints were assessed using risk ratios, both with 95% confidence intervals (CIs). Statistical analyses were performed using Review Manager Web software. Eight RCTs with 1052 patients (754 receiving teplizumab) were included. Teplizumab significantly increased the AUC of C-peptide levels at 6 (MD 0.10 nmol/L, 95% CI 0.05, 0.16), 12 (MD 0.13 nmol/L, 95% CI 0.06, 0.20), 18 (MD 0.18 nmol/L, 95% CI 0.09, 0.27) and 24 months (MD 0.16 nmol/L, 95% CI 0.02, 0.31), significantly reduced HbA1c levels at 6 (MD -0.57%, 95% CI -1.07, -0.08) and 12 months (MD -0.31%, 95% CI -0.59, -0.02), and significantly reduced insulin requirements at 6 (MD -0.12 U/kg, 95% CI -0.16, -0.08), 12 (MD -0.11 U/kg, 95% CI -0.15, -0.07), 18 (MD -0.17 U/kg, 95% CI -0.26, -0.09) and 24 months (MD -0.11 U/kg, 95% CI -0.22, -0.01). Teplizumab increases AUC of C-peptide levels and decreases HbA1c levels and insulin use, without raising serious adverse event risk. AimTo provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM).Materials and MethodsThe PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) comparing teplizumab to placebo for T1DM that reported any of the following outcomes: (1) C‐peptide area under the curve (AUC); (2) glycated haemoglobin (HbA1c) levels; (3) insulin requirements; and (4) adverse events. Heterogeneity was examined with I2 statistics. p values <0.05 were taken to indicate statistical significance. The continuous endpoints were compared through the pooled mean difference (MD) and binary endpoints were assessed using risk ratios, both with 95% confidence intervals (CIs). Statistical analyses were performed using Review Manager Web software.ResultsEight RCTs with 1052 patients (754 receiving teplizumab) were included. Teplizumab significantly increased the AUC of C‐peptide levels at 6 (MD 0.10 nmol/L, 95% CI 0.05, 0.16), 12 (MD 0.13 nmol/L, 95% CI 0.06, 0.20), 18 (MD 0.18 nmol/L, 95% CI 0.09, 0.27) and 24 months (MD 0.16 nmol/L, 95% CI 0.02, 0.31), significantly reduced HbA1c levels at 6 (MD −0.57%, 95% CI −1.07, −0.08) and 12 months (MD −0.31%, 95% CI −0.59, −0.02), and significantly reduced insulin requirements at 6 (MD −0.12 U/kg, 95% CI −0.16, −0.08), 12 (MD −0.11 U/kg, 95% CI −0.15, −0.07), 18 (MD −0.17 U/kg, 95% CI −0.26, −0.09) and 24 months (MD −0.11 U/kg, 95% CI −0.22, −0.01).ConclusionTeplizumab increases AUC of C‐peptide levels and decreases HbA1c levels and insulin use, without raising serious adverse event risk. Abstract Aim To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM). Materials and Methods The PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) comparing teplizumab to placebo for T1DM that reported any of the following outcomes: (1) C‐peptide area under the curve (AUC); (2) glycated haemoglobin (HbA1c) levels; (3) insulin requirements; and (4) adverse events. Heterogeneity was examined with I 2 statistics. p values <0.05 were taken to indicate statistical significance. The continuous endpoints were compared through the pooled mean difference (MD) and binary endpoints were assessed using risk ratios, both with 95% confidence intervals (CIs). Statistical analyses were performed using Review Manager Web software. Results Eight RCTs with 1052 patients (754 receiving teplizumab) were included. Teplizumab significantly increased the AUC of C‐peptide levels at 6 (MD 0.10 nmol/L, 95% CI 0.05, 0.16), 12 (MD 0.13 nmol/L, 95% CI 0.06, 0.20), 18 (MD 0.18 nmol/L, 95% CI 0.09, 0.27) and 24 months (MD 0.16 nmol/L, 95% CI 0.02, 0.31), significantly reduced HbA1c levels at 6 (MD −0.57%, 95% CI −1.07, −0.08) and 12 months (MD −0.31%, 95% CI −0.59, −0.02), and significantly reduced insulin requirements at 6 (MD −0.12 U/kg, 95% CI −0.16, −0.08), 12 (MD −0.11 U/kg, 95% CI −0.15, −0.07), 18 (MD −0.17 U/kg, 95% CI −0.26, −0.09) and 24 months (MD −0.11 U/kg, 95% CI −0.22, −0.01). Conclusion Teplizumab increases AUC of C‐peptide levels and decreases HbA1c levels and insulin use, without raising serious adverse event risk. To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM).AIMTo provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM).The PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) comparing teplizumab to placebo for T1DM that reported any of the following outcomes: (1) C-peptide area under the curve (AUC); (2) glycated haemoglobin (HbA1c) levels; (3) insulin requirements; and (4) adverse events. Heterogeneity was examined with I2 statistics. p values <0.05 were taken to indicate statistical significance. The continuous endpoints were compared through the pooled mean difference (MD) and binary endpoints were assessed using risk ratios, both with 95% confidence intervals (CIs). Statistical analyses were performed using Review Manager Web software.MATERIALS AND METHODSThe PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) comparing teplizumab to placebo for T1DM that reported any of the following outcomes: (1) C-peptide area under the curve (AUC); (2) glycated haemoglobin (HbA1c) levels; (3) insulin requirements; and (4) adverse events. Heterogeneity was examined with I2 statistics. p values <0.05 were taken to indicate statistical significance. The continuous endpoints were compared through the pooled mean difference (MD) and binary endpoints were assessed using risk ratios, both with 95% confidence intervals (CIs). Statistical analyses were performed using Review Manager Web software.Eight RCTs with 1052 patients (754 receiving teplizumab) were included. Teplizumab significantly increased the AUC of C-peptide levels at 6 (MD 0.10 nmol/L, 95% CI 0.05, 0.16), 12 (MD 0.13 nmol/L, 95% CI 0.06, 0.20), 18 (MD 0.18 nmol/L, 95% CI 0.09, 0.27) and 24 months (MD 0.16 nmol/L, 95% CI 0.02, 0.31), significantly reduced HbA1c levels at 6 (MD -0.57%, 95% CI -1.07, -0.08) and 12 months (MD -0.31%, 95% CI -0.59, -0.02), and significantly reduced insulin requirements at 6 (MD -0.12 U/kg, 95% CI -0.16, -0.08), 12 (MD -0.11 U/kg, 95% CI -0.15, -0.07), 18 (MD -0.17 U/kg, 95% CI -0.26, -0.09) and 24 months (MD -0.11 U/kg, 95% CI -0.22, -0.01).RESULTSEight RCTs with 1052 patients (754 receiving teplizumab) were included. Teplizumab significantly increased the AUC of C-peptide levels at 6 (MD 0.10 nmol/L, 95% CI 0.05, 0.16), 12 (MD 0.13 nmol/L, 95% CI 0.06, 0.20), 18 (MD 0.18 nmol/L, 95% CI 0.09, 0.27) and 24 months (MD 0.16 nmol/L, 95% CI 0.02, 0.31), significantly reduced HbA1c levels at 6 (MD -0.57%, 95% CI -1.07, -0.08) and 12 months (MD -0.31%, 95% CI -0.59, -0.02), and significantly reduced insulin requirements at 6 (MD -0.12 U/kg, 95% CI -0.16, -0.08), 12 (MD -0.11 U/kg, 95% CI -0.15, -0.07), 18 (MD -0.17 U/kg, 95% CI -0.26, -0.09) and 24 months (MD -0.11 U/kg, 95% CI -0.22, -0.01).Teplizumab increases AUC of C-peptide levels and decreases HbA1c levels and insulin use, without raising serious adverse event risk.CONCLUSIONTeplizumab increases AUC of C-peptide levels and decreases HbA1c levels and insulin use, without raising serious adverse event risk. |
| Author | Cunha, Luisa Henkes Machado, Rafael Lins de Menezes, Vanessa Grando Alves, Gabriel |
| Author_xml | – sequence: 1 givenname: Gabriel surname: Grando Alves fullname: Grando Alves, Gabriel organization: Federal University of Santa Maria – sequence: 2 givenname: Luisa surname: Cunha fullname: Cunha, Luisa organization: Lusíada University Center – sequence: 3 givenname: Rafael surname: Henkes Machado fullname: Henkes Machado, Rafael organization: University of Southern Santa Catarina – sequence: 4 givenname: Vanessa orcidid: 0009-0000-3854-0377 surname: Lins de Menezes fullname: Lins de Menezes, Vanessa email: vanessalinsdemenezes@gmail.com organization: Ribeirão Preto Medical School, University of São Paulo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38602411$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kctO3TAQhq0KVC7toi9QWeqmXQR8SeKT7hC9IYFY0K4j2xmrRrEdbAcUVn2EPkKfrU9Sn3MoCyRmMyPPN7_16z9AOz54QOgNJUe01PEQ3BFtmhV9gfZp3fKKctbubGZWrTrC9tBBSteEkJqvxEu0x1ctYTWl--jPlTSQFyz9gMEYq6VecDA4wzTa-9lJha3H-SfgHEFmBz5v1ssEmOLBSgUZEnYwjjbP6SM-8XieBplhwGlJGZzMVuMItxbuNr84yPLvr9_Sy3FJNq3VYnkPzt6XGx18jmEcy5ijlWN6hXZNafD6oR-iH18-fz_9Vp1ffj07PTmvNKecVoI2yhBjQDWd4gJqJhiFulagZNsoTbUhwDpCWGe0ZpKyxpRDQdVgiFYdP0Tvt7pTDDczpNw7m3SxJT2EOfWccMG7phV1Qd89Qa_DHIufNdXyTjS14IX6sKV0DClFMP0UrZNx6Snp17H1xXO_ia2wbx8UZ-VgeCT_51SA4y1wZ0dYnlfqP11ebCX_AZsApus |
| Cites_doi | 10.1056/NEJMoa012864 10.2337/db13-0345 10.1056/NEJMoa2306691 10.1016/S0140-6736(11)60931-8 10.1016/S0140-6736(15)60971-0 10.2337/dc18-0494 10.1177/0962280216669183 10.1177/0145445516673998 10.1007/s00125-018-4786-9 10.2337/db13-0236 10.1186/1471-2288-14-135 10.2337/diabetes.54.6.1763 10.1136/bmjopen-2019-033500 10.1016/S2213-8587(23)00267-X 10.1056/NEJMoa043980 10.1136/bmj.315.7109.629 10.1056/NEJMoa2308743 10.1056/NEJMoa2006136 10.1126/science.abh1654 10.1007/s00125-012-2753-4 10.1126/scitranslmed.abc8980 10.1136/bmj.n71 10.2174/1871530320999201209222921 10.1007/s12020-023-03543-z 10.1056/NEJMoa1902226 10.1210/jc.2012-1561 10.1056/NEJMoa1107096 10.2337/dc23-0180 10.1136/bmj.l4898 10.1016/j.clim.2009.04.007 10.1210/jcem-65-1-30 10.1007/s00125-023-06014-2 |
| ContentType | Journal Article |
| Copyright | 2024 John Wiley & Sons Ltd. |
| Copyright_xml | – notice: 2024 John Wiley & Sons Ltd. |
| DBID | NPM AAYXX CITATION 7T5 7TK H94 K9. 7X8 |
| DOI | 10.1111/dom.15581 |
| DatabaseName | PubMed CrossRef Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | PubMed AIDS and Cancer Research Abstracts CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Statistics |
| EISSN | 1463-1326 |
| EndPage | 2661 |
| ExternalDocumentID | 10_1111_dom_15581 38602411 DOM15581 |
| Genre | researchArticle Journal Article |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OC 29F 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~KM ~WT NPM AAYXX CITATION 7T5 7TK H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c3131-715bf0ffeb59b37e42721e44beba65bc1cf0e290029fcc2a125f31371bdf0cb93 |
| IEDL.DBID | DR2 |
| ISSN | 1462-8902 1463-1326 |
| IngestDate | Sat Aug 17 04:33:45 EDT 2024 Thu Oct 10 20:49:35 EDT 2024 Wed Oct 09 16:51:25 EDT 2024 Wed Oct 23 10:16:31 EDT 2024 Sat Aug 24 00:58:45 EDT 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 7 |
| Keywords | T1DM teplizumab type 1 diabetes mellitus meta‐analysis systematic review C‐peptide anti‐CD3 monoclonal antibody |
| Language | English |
| License | 2024 John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3131-715bf0ffeb59b37e42721e44beba65bc1cf0e290029fcc2a125f31371bdf0cb93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-4 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0009-0000-3854-0377 |
| PMID | 38602411 |
| PQID | 3063975473 |
| PQPubID | 1006516 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_3037395674 proquest_journals_3063975473 crossref_primary_10_1111_dom_15581 pubmed_primary_38602411 wiley_primary_10_1111_dom_15581_DOM15581 |
| PublicationCentury | 2000 |
| PublicationDate | July 2024 |
| PublicationDateYYYYMMDD | 2024-07-01 |
| PublicationDate_xml | – month: 07 year: 2024 text: July 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England – name: Oxford |
| PublicationTitle | Diabetes, obesity & metabolism |
| PublicationTitleAlternate | Diabetes Obes Metab |
| PublicationYear | 2024 |
| Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
| References | 2011; 378 2017; 41 2021; 21 1997; 315 2023; 11 2012; 366 2020; 383 2005; 352 2013; 62 2021; 29 2015; 385 2009; 132 2023; 389 2018; 41 2020; 10 2019; 381 2018; 27 2023; 83 2012; 97 2021; 13 2023; 46 1987; 65 2019; 62 2013; 56 2019; 28 2002; 346 2005; 54 2021; 373 2014; 19 2024; 67 2013 2024; 47 e_1_2_9_30_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 American Diabetes Association (e_1_2_9_31_1) 2024; 47 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_37_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 GRADE (e_1_2_9_16_1) 2013 e_1_2_9_27_1 e_1_2_9_29_1 |
| References_xml | – volume: 19 start-page: 135 issue: 14 year: 2014 article-title: Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range publication-title: BMC Med Res Methodol – volume: 21 start-page: 1895 issue: 10 year: 2021 end-page: 1904 article-title: Safety and efficacy of teplizumab for treatment of type one diabetes mellitus: a systematic review and meta‐analysis publication-title: Endocr Metab Immune Disord Drug Targets – volume: 56 start-page: 391 issue: 2 year: 2013 end-page: 400 article-title: Teplizumab treatment may improve C‐peptide responses in participants with type 1 diabetes after the new‐onset period: a randomised controlled trial publication-title: Diabetologia – volume: 385 start-page: 2096 issue: 9982 year: 2015 end-page: 2106 article-title: Care of diabetes in children and adolescents: controversies, changes, and consensus publication-title: Lancet – volume: 10 issue: 3 year: 2020 article-title: Assessing the effect of closed‐loop insulin delivery from onset of type 1 diabetes in youth on residual beta‐cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol publication-title: BMJ Open – volume: 29 issue: 372 year: 2021 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: BMJ – volume: 13 issue: 583 year: 2021 article-title: Teplizumab improves and stabilizes beta cell function in antibody‐positive high‐risk individuals publication-title: Sci Transl Med – volume: 41 start-page: 1917 issue: 9 year: 2018 end-page: 1925 article-title: Low‐dose anti‐Thymocyte globulin (ATG) preserves β‐cell function and improves HbA(1c) in new‐onset type 1 diabetes publication-title: Diabetes Care – volume: 352 start-page: 2598 issue: 25 year: 2005 end-page: 2608 article-title: Insulin needs after CD3‐antibody therapy in new‐onset type 1 diabetes publication-title: N Engl J Med – volume: 46 start-page: 1404 issue: 7 year: 2023 end-page: 1408 article-title: National Trends in hyperglycemia and diabetic ketoacidosis in children, adolescents, and Young adults with type 1 diabetes: a challenge due to age or stage of development, or is new thinking about service provision needed? publication-title: Diabetes Care – volume: 378 start-page: 487 issue: 9790 year: 2011 end-page: 497 article-title: Teplizumab for treatment of type 1 diabetes (Protégé study): 1‐year results from a randomised, placebo‐controlled trial publication-title: Lancet – volume: 28 issue: 366 year: 2019 article-title: RoB 2: a revised tool for assessing risk of bias in randomised trials publication-title: BMJ – volume: 389 start-page: 2140 issue: 23 year: 2023 end-page: 2150 article-title: Baricitinib and β‐cell function in patients with new‐onset type 1 diabetes publication-title: N Engl J Med – volume: 383 start-page: 2007 issue: 21 year: 2020 end-page: 2017 article-title: Golimumab and Beta‐cell function in youth with new‐onset type 1 diabetes publication-title: N Engl J Med – volume: 381 start-page: 603 issue: 7 year: 2019 end-page: 613 article-title: An anti‐CD3 antibody, Teplizumab, in relatives at risk for type 1 diabetes publication-title: N Engl J Med – volume: 62 start-page: 3766 issue: 11 year: 2013 end-page: 3774 article-title: Teplizumab (anti‐CD3 mAb) treatment preserves C‐peptide responses in patients with new‐onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders publication-title: Diabetes – volume: 65 start-page: 30 issue: 1 year: 1987 end-page: 36 article-title: Effects of age, duration and treatment of insulin‐dependent diabetes mellitus on residual beta‐cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group publication-title: J Clin Endocrinol Metab – volume: 346 start-page: 1692 issue: 22 year: 2002 end-page: 1698 article-title: Anti‐CD3 monoclonal antibody in new‐onset type 1 diabetes mellitus publication-title: N Engl J Med – volume: 62 start-page: 3901 issue: 11 year: 2013 end-page: 3908 article-title: Teplizumab preserves C‐peptide in recent‐onset type 1 diabetes: two‐year results from the randomized, placebo‐controlled Protégé trial publication-title: Diabetes – volume: 97 start-page: 4383 issue: 12 year: 2012 end-page: 4389 article-title: The T1D exchange clinic registry publication-title: J Clin Endocrinol Metab – volume: 62 start-page: 655 issue: 4 year: 2019 end-page: 664 article-title: Treatment of type 1 diabetes with teplizumab: clinical and immunological follow‐up after 7 years from diagnosis publication-title: Diabetologia – volume: 41 start-page: 323 issue: 2 year: 2017 end-page: 339 article-title: Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data publication-title: Behav Modif – volume: 315 start-page: 629 issue: 7109 year: 1997 end-page: 634 article-title: Bias in meta‐analysis detected by a simple, graphical test publication-title: BMJ – volume: 27 start-page: 1785 issue: 6 year: 2018 end-page: 1805 article-title: Optimally estimating the sample mean from the sample size, median, mid‐range, and/or mid‐quartile range publication-title: Stat Methods Med Res – volume: 83 start-page: 648 year: 2023 end-page: 658 article-title: Anti‐CD3 monoclonal antibodies in treatment of type 1 diabetes: a systematic review and meta‐analysis publication-title: Endocrine – volume: 366 start-page: 433 issue: 5 year: 2012 end-page: 442 article-title: GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus publication-title: N Engl J Med – volume: 11 start-page: 915 issue: 12 year: 2023 end-page: 925 article-title: C‐peptide and metabolic outcomes in trials of disease modifying therapy in new‐onset type 1 diabetes: an individual participant meta‐analysis publication-title: Lancet Diabetes Endocrinol – volume: 132 start-page: 166 issue: 2 year: 2009 end-page: 173 article-title: Treatment of patients with new onset type 1 diabetes with a single course of anti‐CD3 mAb Teplizumab preserves insulin production for up to 5 years publication-title: Clin Immunol – volume: 47 start-page: S158 issue: Supplement_1 year: 2024 end-page: S178 article-title: 8. Pharmacologic approaches to glycemic treatment publication-title: Diabetes Care – volume: 54 start-page: 1763 issue: 6 year: 2005 end-page: 1769 article-title: A single course of anti‐CD3 monoclonal antibody hOKT3gamma1(ala‐ala) results in improvement in C‐peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes publication-title: Diabetes – volume: 373 start-page: 510 issue: 6554 year: 2021 end-page: 516 article-title: Immunotherapy: building a bridge to a cure for type 1 diabetes publication-title: Science – volume: 67 start-page: 27 issue: 1 year: 2024 end-page: 41 article-title: A first‐in‐human, open‐label phase 1b and a randomised, double‐blind phase 2a clinical trial in recent‐onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab publication-title: Diabetologia – volume: 389 start-page: 2151 issue: 23 year: 2023 end-page: 2161 article-title: Teplizumab and β‐cell function in newly diagnosed type 1 diabetes publication-title: N Engl J Med – year: 2013 – ident: e_1_2_9_22_1 doi: 10.1056/NEJMoa012864 – ident: e_1_2_9_9_1 doi: 10.2337/db13-0345 – ident: e_1_2_9_28_1 doi: 10.1056/NEJMoa2306691 – ident: e_1_2_9_8_1 doi: 10.1016/S0140-6736(11)60931-8 – ident: e_1_2_9_3_1 doi: 10.1016/S0140-6736(15)60971-0 – ident: e_1_2_9_26_1 doi: 10.2337/dc18-0494 – ident: e_1_2_9_17_1 doi: 10.1177/0962280216669183 – ident: e_1_2_9_13_1 doi: 10.1177/0145445516673998 – ident: e_1_2_9_37_1 doi: 10.1007/s00125-018-4786-9 – ident: e_1_2_9_25_1 doi: 10.2337/db13-0236 – volume: 47 start-page: S158 issue: 1 year: 2024 ident: e_1_2_9_31_1 article-title: 8. Pharmacologic approaches to glycemic treatment publication-title: Diabetes Care contributor: fullname: American Diabetes Association – ident: e_1_2_9_18_1 doi: 10.1186/1471-2288-14-135 – ident: e_1_2_9_23_1 doi: 10.2337/diabetes.54.6.1763 – ident: e_1_2_9_35_1 doi: 10.1136/bmjopen-2019-033500 – ident: e_1_2_9_19_1 – ident: e_1_2_9_33_1 doi: 10.1016/S2213-8587(23)00267-X – ident: e_1_2_9_29_1 doi: 10.1056/NEJMoa043980 – ident: e_1_2_9_15_1 doi: 10.1136/bmj.315.7109.629 – ident: e_1_2_9_20_1 doi: 10.1056/NEJMoa2308743 – ident: e_1_2_9_27_1 doi: 10.1056/NEJMoa2006136 – ident: e_1_2_9_2_1 doi: 10.1126/science.abh1654 – volume-title: Handbook for grading quality of evidence and strength of recommendations year: 2013 ident: e_1_2_9_16_1 contributor: fullname: GRADE – ident: e_1_2_9_24_1 doi: 10.1007/s00125-012-2753-4 – ident: e_1_2_9_5_1 – ident: e_1_2_9_7_1 doi: 10.1126/scitranslmed.abc8980 – ident: e_1_2_9_11_1 doi: 10.1136/bmj.n71 – ident: e_1_2_9_10_1 doi: 10.2174/1871530320999201209222921 – ident: e_1_2_9_32_1 doi: 10.1007/s12020-023-03543-z – ident: e_1_2_9_6_1 doi: 10.1056/NEJMoa1902226 – ident: e_1_2_9_12_1 – ident: e_1_2_9_36_1 doi: 10.1210/jc.2012-1561 – ident: e_1_2_9_30_1 doi: 10.1056/NEJMoa1107096 – ident: e_1_2_9_4_1 doi: 10.2337/dc23-0180 – ident: e_1_2_9_14_1 doi: 10.1136/bmj.l4898 – ident: e_1_2_9_21_1 doi: 10.1016/j.clim.2009.04.007 – ident: e_1_2_9_34_1 doi: 10.1210/jcem-65-1-30 – ident: e_1_2_9_38_1 doi: 10.1007/s00125-023-06014-2 |
| SSID | ssj0004387 |
| Score | 2.4741485 |
| SecondaryResourceType | review_article |
| Snippet | Aim
To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM).
Materials and Methods
The... To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM). The PubMed, Embase and Cochrane... Abstract Aim To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM). Materials and... AimTo provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM).Materials and MethodsThe... To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM).AIMTo provide updated efficacy... |
| SourceID | proquest crossref pubmed wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 2652 |
| SubjectTerms | Adverse events anti‐CD3 monoclonal antibody Clinical trials C‐peptide Diabetes Diabetes mellitus (insulin dependent) Hemoglobin Insulin Meta-analysis Monoclonal antibodies Peptides Statistical analysis Statistics systematic review T1DM teplizumab type 1 diabetes mellitus |
| Title | Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta‐analysis of randomized controlled trials |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fdom.15581 https://www.ncbi.nlm.nih.gov/pubmed/38602411 https://www.proquest.com/docview/3063975473 https://www.proquest.com/docview/3037395674/abstract/ |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwEB4hDogL5afQBYoM6oFLVnHiJJieEBQhJEBqi8QBKbK9toRgs4hNDuyJR-AReDaehBnnh9IKqeISWYr_Ens8nz3jbwC-RWlE1hgZuMiZAPGtDnZUlgSo7JwRQoT4JG-L0_ToXBxfJBdT8L29C1PzQ3QHbiQZfr0mAVd6_IeQD0bDPipDf-2aiPQIEP18pY4SsQ-OhwsBSrwkL5751ounK_lWF_0DMN_iVa9wDj_BZdvV2s_kul-Vum8mf7E4fvBb5mGuAaJsr545CzBli0WYOWlM7Uvw9Es5W94zVQyYJZ4JZe7ZyLHSImydVEOl2VXBED6yzlfdv8Z9LeOsPdJlQyL8LKvxLtsrWHVL5wsD9kofzeqrM76VoS3V88OjamhSqDZUpNjpqwmWaXzqbzDpI42MP8P54Y_f-0dBE84hMDGPeZDxRLvQOasTqePMigh3n1YIbbVKE224caGNJNkJnTGRQujlsGDG9cCFRst4GaaLUWG_AOMm3XEqlEboRAgsHyrHIyWlzawUWdiDrXZg89uatSNvdzvY7dz_6x6st0OeN4I7zmNv6aSAzD3Y7F6jyJEdRRV2VFGemMybaSZ6sFJPla6VmGJ6CY6Vb_sBf7_5_ODsxCdW_z_rGsxGWH3tLrwO0-VdZb8iKCr1hp_9L4e2Cwc |
| link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fTxQxEJ8QTMQXRUE8RSmEB1_2st3t7lLjCxHJoRwkCAkvZNP22uSit0e83QfuyY_gR_Cz-Umc6f5BMCTEl02T7bTdbX-d6cx0BmA7SiOyxsjARc4EKN_qYEdlSYDMzhkhRIhP8rY4Sgdn4tN5cr4A79u7MHV8iE7hRsjw-zUBnBTSf6F8NJ30kRvSvesHCPeEYLl3ch08SsQ-PR5uBYh5SX48y60fT0d6kxv9I2LelFg9y9l_AhftYGtPk6_9qtR9M78Vx_F_v2YZHjeyKNutF89TWLDFM3g4bKztK_Dri3K2vGKqGDFLoSaUuWJTx0qLkuu8mijNxgVDCZJ17ur-NR5tGWetVpdNKOZnWc3esd2CVZekYhix6wjSrL4943uZ2FL9_vFTNZFSqDXkpTjo8RxpGrf6b1j0yUZmq3C2__H0wyBoMjoEJuYxDzKeaBc6Z3UidZxZEeEB1AqhrVZpog03LrSRJFOhMyZSKH05JMy4HrnQaBk_h8ViWtgXwLhJd5wKpRE6EQLpQ-V4pKS0mZUiC3uw1c5sflkH7sjbAw8OO_f_ugfr7ZznDXZneeyNnZSTuQeb3WtEHZlSVGGnFdWJycKZZqIHa_Va6XqJKa2X4Nj4Wz_jd3ef7x0PfeHl_atuwNLgdHiYHx4cfX4FjyLsqvYeXofF8ntlX6OMVOo3Hgp_ACqZDyc |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hkFAvhb63UOpWPfSSVfxIgssJdVnRB7Rqi8ShUmQ7toTKZlfd5MCe-hP4Cfw2fknHzgMoqlT1ElmKx3Zij-cbz3gG4BVLmbfGyMgxZyLEtzraVlkSobBzRggR49N7Wxym-0fi_XFyvAQ73V2YJj5Ef-DmOSPs157BZ4W7xuTFdDJEYeivXa-IlDOveY2-XMWOEjxkx8OdAFleejee9c6Npye9KYxuIcybgDVInPEafO_G2jia_BjWlR6axR9hHP_zY9bhbotEyW6zdO7Bki3vw-pBa2t_ABdflbPVGVFlQawPNKHMGZk6UlnErYt6ojQ5KQniR9I7q4fXqNgSSrozXTLxET-rev6G7JaknvkDhoJcxY8mzd2Z0MvEVury17lq46T41lCS4qBPFkjTOtWfYjGkGpk_hKPx3re3-1GbzyEynHIaZTTRLnbO6kRqnlnBUP20QmirVZpoQ42LLZPeUOiMYQqxl0PCjOrCxUZL_giWy2lpnwChJt12KpZG6EQIpI-Vo0xJaTMrRRYP4GU3sfmsCduRd-oODjsP_3oAm92U5y3nznMeTJ0-I_MAXvSvkee8IUWVdlr7OtzbN9NMDOBxs1T6XrhP6iUoNv46TPjfu89Hnw5C4em_V30Oq59H4_zju8MPG3CHYU-N6_AmLFc_a_sMAVKltwIj_Ab_2g3W |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+efficacy+of+teplizumab+in+the+treatment+of+type+1+diabetes+mellitus%3A+An+updated+systematic+review+and+meta-analysis+of+randomized+controlled+trials&rft.jtitle=Diabetes%2C+obesity+%26+metabolism&rft.au=Grando+Alves%2C+Gabriel&rft.au=Cunha%2C+Luisa&rft.au=Henkes+Machado%2C+Rafael&rft.au=Lins+de+Menezes%2C+Vanessa&rft.date=2024-07-01&rft.eissn=1463-1326&rft_id=info:doi/10.1111%2Fdom.15581&rft_id=info%3Apmid%2F38602411&rft.externalDocID=38602411 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-8902&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-8902&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-8902&client=summon |